ERBB2 and breast cancer: Importantly, adjuvant olaparib after completion of local treatment and (neo)adjuvant CT were recently associated with significantly longer survival free of invasive (HR 0.58; 95% CI 0.41–0.82; p < 0.001) or distant disease (HR 0.57; 95%CI 0.39–0.83; p = 0.02) compared to placebo in 1836 patients with high-risk, HER2-negative BC and gBRCA1 or gBRCA2 in the OlympiA trial [51].